^
    Back
    Association details:
    Biomarker:CD163 underexpression
    Cancer:Hepatocellular Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EASL-ILC 2021
    Title:

    Checkmate 040 Cohort 5: long-term efficacy and safety of nivolumab in patients with ChildPugh B advanced hepatocellular carcinoma and associations between baseline biomarker analyses and outcomes

    Published date:
    06/26/2021
    Excerpt:
    Patients with CPB 7 or 8 aHCC (sorafenib naive n = 25; sorafenib treated n = 24) received nivolumab 240 mg intravenously for 30 minutes every 2 weeks...Lower tumor expression of PD-1 and CD163 was associated with longer OS (Fig)...